These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 6999984)
41. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. Roos JF; Bulitta J; Lipman J; Kirkpatrick CM J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209 [TBL] [Abstract][Full Text] [Related]
42. [Comparison of bactericidal effects of four aminoglycoside antibiotics: amikacin, gentamicin, kanamycin and tobramycin (author's transl)]. Drugeon HB; Courtieu AL Ann Microbiol (Paris); 1979 Apr; 130A(3):331-43. PubMed ID: 114083 [TBL] [Abstract][Full Text] [Related]
43. Topoisomerase I inhibitor evodiamine acts as an antibacterial agent against drug-resistant Klebsiella pneumoniae. Wu JY; Chang MC; Chen CS; Lin HC; Tsai HP; Yang CC; Yang CH; Lin CM Planta Med; 2013 Jan; 79(1):27-9. PubMed ID: 23161424 [TBL] [Abstract][Full Text] [Related]
44. [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009]. Hamouche E; Sarkis DK Pathol Biol (Paris); 2012 Jun; 60(3):e15-20. PubMed ID: 21719212 [TBL] [Abstract][Full Text] [Related]
45. Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study. Hawser SP; Badal RE; Bouchillon SK; Hoban DJ; Hsueh PR Int J Antimicrob Agents; 2010 Sep; 36(3):293-4. PubMed ID: 20598511 [No Abstract] [Full Text] [Related]
46. In vitro antimicrobial activity of N-acetylcysteine against bacteria colonising central venous catheters. Mansouri MD; Darouiche RO Int J Antimicrob Agents; 2007 Apr; 29(4):474-6. PubMed ID: 17293092 [No Abstract] [Full Text] [Related]
47. Cell-wall-inhibiting antibiotic combinations with activity against multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Hickman RA; Hughes D; Cars T; Malmberg C; Cars O Clin Microbiol Infect; 2014 Apr; 20(4):O267-73. PubMed ID: 24118201 [TBL] [Abstract][Full Text] [Related]
48. Zhao M; Lepak AJ; Marchillo K; VanHecker J; Andes DR Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987156 [TBL] [Abstract][Full Text] [Related]
49. Comparative bactericidal effect of ceforanide (BL-S 786) and five other cephalosporins in an in vitro pharmacokinetic model. Randolph JA; Buck RE; Price KE; Leitner F J Antibiot (Tokyo); 1979 Jul; 32(7):727-33. PubMed ID: 396292 [TBL] [Abstract][Full Text] [Related]
50. Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients. Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Chu Y; Chen S; Cao B; Su J; Duan Q; Zhang S; Shao H; Kong H; Gui B; Hu Z; Badal R; Xu Y BMC Infect Dis; 2017 Dec; 17(1):776. PubMed ID: 29254478 [TBL] [Abstract][Full Text] [Related]
51. Bactericidal activity of cephalosporins in an in vitro model simulating serum levels. Nishida M; Murakawa T; Kamimura T; Okada N Antimicrob Agents Chemother; 1978 Jul; 14(1):6-12. PubMed ID: 356725 [TBL] [Abstract][Full Text] [Related]
52. Evaluation of pooled human urine and synthetic alternatives in a dynamic bladder infection in vitro model simulating oral fosfomycin therapy. Abbott IJ; van Gorp E; Wijma RA; Meletiadis J; Mouton JW; Peleg AY J Microbiol Methods; 2020 Apr; 171():105861. PubMed ID: 32035114 [TBL] [Abstract][Full Text] [Related]
53. Comparative in vitro antibacterial activities of cefetamet (Ro 15-8074/005), a new oral cephalosporin, and eight other oral antimicrobials. Rozgonyi F; Papp-Falusi E; Varga J; Rozgonyi-Szitha K J Chemother; 1989 Jul; 1(4 Suppl):119-22. PubMed ID: 16312332 [No Abstract] [Full Text] [Related]
54. In vitro activity of 10 antimicrobial agents against bacteria isolated from cows with clinical mastitis. Guérin-Faublée V; Carret G; Houffschmitt P Vet Rec; 2003 Apr; 152(15):466-71. PubMed ID: 12723630 [TBL] [Abstract][Full Text] [Related]
55. Changes in serum sensitivity and hydrophobicity in a clinical isolate of Klebsiella pneumoniae treated with subinhibitory concentrations of aminoglycosides. Hostacká A Zentralbl Bakteriol; 1998 Dec; 288(4):519-26. PubMed ID: 9987190 [TBL] [Abstract][Full Text] [Related]
56. Non-antibiotics reverse resistance of bacteria to antibiotics. Kristiansen JE; Thomsen VF; Martins A; Viveiros M; Amaral L In Vivo; 2010; 24(5):751-4. PubMed ID: 20952744 [TBL] [Abstract][Full Text] [Related]
57. In vitro bactericidal activity of cefepime and cefpirome against clinical isolates at Karachi. Arsalan A; Naqvi SB; Ali SA; Ahmed S; Shakeel O Pak J Pharm Sci; 2015 May; 28(3):841-7. PubMed ID: 26004702 [TBL] [Abstract][Full Text] [Related]
58. The designer proline-rich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models. Szabo D; Ostorhazi E; Binas A; Rozgonyi F; Kocsis B; Cassone M; Wade JD; Nolte O; Otvos L Int J Antimicrob Agents; 2010 Apr; 35(4):357-61. PubMed ID: 20031377 [TBL] [Abstract][Full Text] [Related]
59. [In vitro susceptibility of Escherichia coli and Klebsiella sp. to antibiotics]. Igari J; Shitara M; Shitara M; Yoshimoto K; Hayashi Y Jpn J Antibiot; 1990 Apr; 43(4):659-69. PubMed ID: 2199690 [TBL] [Abstract][Full Text] [Related]
60. [Correlation between antibacterial activity of some cephalosporins and pharmacokinetic properties "in vitro" (author's transl)]. Tamassia V; Meinardi G; Grasso S; de Carneri I Quad Sclavo Diagn; 1979 Jun; 15 Suppl 1():785-92. PubMed ID: 400257 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]